logo

KREBSBIO vs VENUSREM: Stock Comparison

KREBS BIOCHEMICALS & IND vs VENUSREMUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

VENUSREM is the larger company by market capitalisation. KREBS BIOCHEMICALS & IND shows a lower P/E, while VENUSREM shows a higher dividend yield, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KREBSBIO leads 2; VENUSREM leads 7 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KREBSBIOVENUSREM

Valuation lens

What price are you paying?

Market CapContext only
₹125 Cr
₹1,924 Cr
P/E RatioKREBSBIO has the lower reading
0x ✓
16.56x
P/B RatioKREBSBIO has the lower reading
0x ✓
2.9x
EPSVENUSREM has the higher reading
₹-1.15
₹17.18 ✓
Book ValueContext only
—
₹496.56
Dividend YieldVENUSREM has the higher reading
0%
0.66% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
VENUSREM is the larger company
₹1,924 Cr vs ₹125 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 16.56x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 2.9x
EPS
VENUSREM has higher earnings per share
₹17.18 vs ₹-1.15
Dividend Yield
VENUSREM has a higher dividend yield
0.66% vs 0%
Revenue Growth (TTM YoY)
VENUSREM has faster revenue growth
33% vs 11.6%
EPS Growth (TTM YoY)
VENUSREM has faster EPS growth
126.4% vs 0%
ROCE
VENUSREM has a higher ROCE
16.2% vs -15.89%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKREBSBIOVENUSREM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKREBSBIOVENUSREM
Live Price₹57.48₹1,796.7
Day Change2.53%0.03%
Volume3,5701.17 L
52-Week High₹76.85₹1,880
52-Week Low₹38.33₹432.1
Distance from 52W High-25.2%-4.43%

Valuation

MetricKREBSBIOVENUSREM
Market Cap₹125 Cr₹1,924 Cr
P/E Ratio0x16.56x
P/B Ratio0x2.9x
EPS₹-1.15₹17.18
Book Value—₹496.56
Dividend Yield0%0.66%

Growth

MetricKREBSBIOVENUSREM
Revenue Growth (TTM YoY)11.6%33%
EPS Growth (TTM YoY)0%126.4%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricKREBSBIOVENUSREM
ROE—15.49%
ROCE-15.89%16.2%
Net Margin-71.35%13.35%
Operating Margin-41.49%17.56%
Debt to Equity—0x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricKREBSBIOVENUSREM
Promoter Holding72.74%41.76%
FII Holding0.5%3.14%▲ 0.22 pp
DII Holding0%0.74%▼ 0.15 pp
Public Holding26.76%54.36%▼ 0.07 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KREBS BIOCHEMICALS & IND and VENUSREM.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.